Ropinirole
- Generic Name
- Ropinirole
- Brand Names
- Requip
- Drug Type
- Small Molecule
- Chemical Formula
- C16H24N2O
- CAS Number
- 91374-21-9
- Unique Ingredient Identifier
- 030PYR8953
- Background
Ropinirole, also known as ReQuip, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome , . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome .
In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole .
- Indication
For the treatment of the signs and symptoms of Parkinson's disease and for the treatment of primary moderate-severe restless legs syndrome .
- Associated Conditions
- Idiopathic Parkinson's Disease, Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)
The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 46
- Registration Number
- NCT00830219
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States
Ropinirole 0.25 mg Tablets Under Fasting Conditions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2009-09-11
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 44
- Registration Number
- NCT00829504
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States
Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 302
- Registration Number
- NCT00823836
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions
- Conditions
- Parkinson's DiseaseRestless Leg Syndrome
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 30
- Registration Number
- NCT00673088
A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions
- Conditions
- Restless Leg SyndromeParkinson's Disease
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 29
- Registration Number
- NCT00674310
Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2013-05-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 76
- Registration Number
- NCT00650104
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States
Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type
- Conditions
- Unverricht-Lundborg Syndrome
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2008-03-19
- Lead Sponsor
- University of Turku
- Target Recruit Count
- 16
- Registration Number
- NCT00639119
- Locations
- 🇫🇮
Turku university central hospital, Department of neurology, Turku, Finland
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
- Conditions
- Parkinson DiseaseParkinson's Disease
- Interventions
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 419
- Registration Number
- NCT00632736
- Locations
- 🇬🇧
GSK Investigational Site, Swansea, United Kingdom
Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome
- Conditions
- Restless Legs Syndrome
- Interventions
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 35
- Registration Number
- NCT00530790
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole
- Conditions
- Parkinson Disease
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT00460148
- Locations
- 🇿🇦
GSK Investigational Site, George, Eastern Cape, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.